Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 13Thoracic 3Gastrointestinal 2Sarcoma 1NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 3Carcinoid Tumor 2Pheochromocytoma 1Paraganglioma 1Neuroblastoma 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adrenal Gland Neoplasms 1

Interventions

Everolimus 2romidepsin 1regorafenib 1exemestane 1entrectinib 1cabozantinib 1alectinib 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Lactones 1LY2584702 1Injections 1Immunotherapy 1Erlotinib Hydrochloride 1Drug Therapy 1Depsipeptides 1Clinical Trials, Phase II as Topic 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Erlotinib Hydrochloride × NET × Clear all
NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
29 enrolled 19 charts
EndocrineGenitourinaryNETThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡